Flonase approved by U.S.FDA

Flonase approved by U.S.FDA

Nemera metering dose pump and actuator for Flonase Allergy Relief has been approved by the U.S. FDA

Nemera, one of the world leaders in the design, development and manufacturing of drug delivery solutions, is happy to announce that its SP270+ metering dose pump and actuator were recently approved by the U.S. Food and Drug Administration (FDA) for Flonase Allergy Relief. This intranasal spray, available over-the-counter, relieves allergy symptoms including nasal congestion, sneezing, itchy, watery eyes, and runny nose.

 

FLONASE

This last approval demonstrates Nemera’s expertise to support client nasal drug product development to meet the highest quality standards of the pharmaceutical industry.

Nemera offers a wide portfolio of off-the-shelf devices and services for nasal drug delivery, from its track-record SP270+ reference to its latest Advancia® new generation nasal spray platform, serving product variations and new product developments.

With established blockbuster market references, Nemera is your privileged partner for your nasal spray project!

For further information: www.nemera.net

Contact:   information@nemera.net


About Nemera

Nemera is a world leader in the design, development, and manufacturing of drug delivery devices for the pharmaceutical, biotechnology and generics industries. Nemera offers a comprehensive portfolio of products and services across ophthalmology, nasal, inhalation, dermal, transdermal and parenteral delivery. Nemera’s vision is to be the most patient-centric drug delivery device company. Nemera always puts patients first, providing high-quality solutions that have a demonstrable impact on patients’ health

Nemera’s newly branded Insight Innovation Center, with offices in North America and Europe, provides consultative services to support your overall device strategy. Providing user research, Human Factors, User Experience design, and Design for manufacturing, the Insight Innovation Center can help customers navigate their device strategy for both novel and platform solutions. Users are at the center of everything that we do in our effort to always put patients first.